Regulatory MSD secures EC approval for Enflonsia to prevent infant RSV infection Pharmaceutical Business ReviewThis approval authorises Enflonsia's marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway.RegulatoryInfectious DiseaseRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Business Review This approval authorises Enflonsia’s marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway. RegulatoryInfectious DiseaseRead full story Post navigation Previous: UCB to purchase Neurona and NRTX-1001 for $1.15bnNext: UCB to purchase Neurona and NRTX-1001 for $1.15bn Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
